Evaluation of a liquid bead array system for high-risk human papillomavirus detection and genotyping in comparison with Hybrid Capture II, DNA chip and sequencing methods
Since persistent infection with high-risk human papillomavirus (HPV) is a known cause of high-grade cervical intraepithelial neoplasia and cervical cancer, several HPV DNA detection methods have been developed during the last decade. The Hybrid Capture II (HCII) assay, which allows detection of 13 high-risk HPVs, has been well validated; however, it does not provide any genotype-specific information. The oncogenic activity of HPV is dependent on its genotype. The prophylactic effects of HPV vaccines are based on L1 virus-like particles and are limited mainly to infections corresponding to the HPV type used to develop the immunogen. Therefore, accurate detection and genotyping are important for treatment as well as screening. A newly developed HPV genotyping system using a liquid bead array was evaluated with 286 cervical samples and the results were compared to two commercially available methods, i.e. the HCII and HPV DNA chip assays, and sequencing. The sensitivity for detection of high-risk HPV was 85.3 % (HCII), 94.7 % (DNA chip) and 99.0 % (liquid bead array). The liquid bead array showed almost perfect agreement (κ=0.95) with genotype information confirmed by sequencing, while substantial agreement (κ=0.8) was observed between DNA chip and sequencing. Furthermore, the liquid bead array had superior detection of 26 HPVs (16 high-risk and 10 low-risk types) and has proven to be as accurate as sequencing in identifying individual HPV types, even in cases with multiple HPV infections.
CoutléeF.,
RouleauD.,
FerenczyA.,
FrancoE.2005; The laboratory diagnosis of genital human papillomavirus infections. Can J Infect Dis Med Microbiol 16:83–91
CoutléeF.,
MayrandM.,
RogerM.,
FrancoE. L.2009; Detection and typing of human papillomavirus nucleic acids in biological fluids. Public Health Genomics 12:308–318[CrossRef]
GeraetsD. T.,
HeidemanD. A. M.,
De KoningM. N. C.,
SnijdersP. J. F.,
Van AlewijkD. C. J. G.,
MeijerC. J. L. M.,
Van DoornL. J.,
QuintW. G. V.2009; High-throughput genotyping of high-risk HPV by the digene HPV genotyping LQ test using GP5+/6+-PCR and xMAP technology. J Clin Virol 46:S21–S26
HanJ.,
SwanD. C.,
SmithS. J.,
LumS. H.,
SefersS. E.,
UngerE. R.,
TangY.-W.2006; Simultaneous amplification and identification of 25 human papillomavirus types with Templex technology. J Clin Microbiol 44:4157–4162[CrossRef]
HarperD. M.,
FrancoE. L.,
WheelerC. M.,
MoscickiA. B.,
RomanowskiB.,
Roteli-MartinsC. M.,
JenkinsD.,
SchuindA.,
Costa ClemensS. A.,
DubinG.2006; Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367:1247–1255[CrossRef]
HesselinkA. T.,
BulkmansN. W. J.,
BerkhofJ.,
LorinczA. T.,
MeijerC. J. L. M.,
SnijdersP. J. F.2006; Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 44:3680–3685[CrossRef]
JiangH. L.,
ZhuH. H.,
ZhouL. F.,
ChenF.,
ChenZ.2006; Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system. J Med Microbiol 55:715–720[CrossRef]
MuñozN.,
BoschF. X.,
De SanjoséS.,
HerreroR.,
CastellsaguéX.,
ShahK. V.,
SnijdersP. J. F.,
MeijerC. J. L. M. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group; 2003; Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527[CrossRef]
OchiH.,
KondoK.,
MatsumotoK.,
OkiA.,
YasugiT.,
FurutaR.,
HiraiY.,
YoshikawaH.,
KandaT.2008; Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol 15:1536–1540[CrossRef]
OhY.,
BaeS. M.,
KimY.-W.,
ChoiH.-S.,
NamG.-H.,
HanS.-J.,
ParkC. H.,
ChoY.,
HanB.-D.,
AhnW. S.2007; Polymerase chain reaction-based fluorescent Luminex assay to detect the presence of human papillomavirus types. Cancer Sci 98:549–554[CrossRef]
RemmerbachT. W.,
BrinckmannU. G.,
HemprichA.,
ChekolM.,
KühndelK.,
LiebertU. G.2004; PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol 30:302–308[CrossRef]
Van DoornL.-J.,
QuintW.,
KleterB.,
MolijnA.,
ColauB.,
MartinM. T.,
Kravang-In Torrez-MartinezN.,
PeytonL.,
WheelerC. M.2002; Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF10 line probe assay. J Clin Microbiol 40:979–983[CrossRef]
VillaL. L.,
AultK. A.,
GiulianoA. R.,
CostaR. L.,
PettaC. A.,
AndradeR. P.,
BrownD. R.,
FerenczyA.,
HarperD. M.,
other authorsC.
2006; Immunologic responses following administration of a vaccine targeting human papillomavirus types 6/11/16, and 18. Vaccine 24:5571–5583[CrossRef]
WinderD. M.,
BallS. L. R.,
VaughanK.,
HannaN.,
WooY. L.,
FränzerJ.,
SterlingJ. C.,
StanleyM. A.,
SudhoffH.,
GoonP. K. C.2009; Sensitive HPV detection in oropharyngeal cancers. BMC Cancer 9:440[CrossRef]
Evaluation of a liquid bead array system for high-risk human papillomavirus detection and genotyping in comparison with Hybrid Capture II, DNA chip and sequencing methods